Spotlight Asset Group’s TG Therapeutics TGTX Stock Holding History

Spotlight Asset Group’s Portfolio TGTX Stock Details TGTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-20,000	Closed	-$6K	–	256
2023 Q1	$6K	Buy	+20,000	New	+$304K	0.01%	77
2022 Q3	$6K	Buy	+20,000	New	+$131K	0.01%	77
2021 Q1	–	Sell	-20,000	Closed	-$664K	–	152
2020 Q4	$664K	Hold	20,000	–	–	0.25%	62
2020 Q3	$190K	Hold	20,000	–	–	0.07%	135
2020 Q2	$96K	Buy	20,000 +10,000	+100%	+$161K	0.04%	135
2020 Q1	$22K	Hold	10,000	–	–	0.01%	115
2019 Q4	$14K	Buy	+10,000	New	+$76K	0.01%	127

Other funds holding TGTX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return

Pictet Asset Management Carouge, Switzerland $94.8B AUM 24.11% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Spotlight Asset Group's TGTX Position: Q2 2024 in Review

Spotlight Asset Group held its TG Therapeutics (TGTX) position steady in Q2 2024 at 82,100 shares worth $1.46M. The position accounts for 1.02% of the portfolio, ranked #23.

Spotlight Asset Group first reported a position in TGTX in Q4 2019 and has held it in 15 quarters since. The position peaked at $3.62M in Q1 2021. 259 funds tracked by Wall St. Rank hold TGTX as of Q2 2024.

Spotlight Asset Group held 82,100 shares of TG Therapeutics worth $1.46M as of Q2 2024.
Spotlight Asset Group left its TG Therapeutics share count unchanged in Q2 2024.
TG Therapeutics made up 1.02% of Spotlight Asset Group's portfolio in Q2 2024, its #23 holding.
Spotlight Asset Group first reported a position in TG Therapeutics in Q4 2019 and has held it in 15 quarters since.
Spotlight Asset Group's TG Therapeutics position peaked at $3.62M in Q1 2021.
259 funds tracked by Wall St. Rank held TG Therapeutics as of Q2 2024.

Based on Spotlight Asset Group's 13F filing for Q2 2024, filed 24 Jul 2024.